Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Gene therapy in vascular medicine: recent advances and future perspectives
Autore:
Morishita, R; Aoki, M; Kaneda, Y; Ogihara, T;
Indirizzi:
Osaka Univ, Grad Sch Med, Div Gene Therapy Sci, Suita, Osaka 5650871, Japan Osaka Univ Suita Osaka Japan 5650871 apy Sci, Suita, Osaka 5650871, Japan Osaka Univ, Grad Sch Med, Dept Geriatr Med, Suita, Osaka 5650871, Japan Osaka Univ Suita Osaka Japan 5650871 atr Med, Suita, Osaka 5650871, Japan
Titolo Testata:
PHARMACOLOGY & THERAPEUTICS
fascicolo: 2, volume: 91, anno: 2001,
pagine: 105 - 114
SICI:
0163-7258(200108)91:2<105:GTIVMR>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
HEPATOCYTE GROWTH-FACTOR; TRANSCRIPTION FACTOR DECOY; MUSCLE CELL-PROLIFERATION; CORONARY-ARTERY DISEASE; IN-VIVO TRANSFECTION; RAT CAROTID-ARTERY; KAPPA-B; ADENOVIRUS VECTOR; PHOSPHOROTHIOATE OLIGONUCLEOTIDE; RIBOZYME OLIGONUCLEOTIDES;
Keywords:
cis-element decoy; antisense; angiogenesis; VEGF; restenosis;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
62
Recensione:
Indirizzi per estratti:
Indirizzo: Morishita, R Osaka Univ, Grad Sch Med, Div Gene Therapy Sci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan Osaka Univ 2-2 Yamadaoka Suita Osaka Japan 5650871 871, Japan
Citazione:
R. Morishita et al., "Gene therapy in vascular medicine: recent advances and future perspectives", PHARM THERA, 91(2), 2001, pp. 105-114

Abstract

Gene therapy is emerging as a potential strategy for the treatment of cardiovascular diseases, such as restenosis after angioplasty, vascular bypass graft occlusion, and transplant coronary vasculopathy, for which no known effective therapy exists. The first human trial in cardiovascular disease was started in 1994 to treat peripheral vascular disease using vascular endothelial growth factor. In addition, therapeutic angiogenesis using the vascular endothelial growth factor gene was applied in the treatment of ischemicheart disease. The results from these clinical trials seem to exceed expectation, Improvement of clinical symptoms in peripheral arterial disease andischemic heart disease has been reported. At least five different potent angiogenic growth factors have been tested in clinical trials to treat peripheral arterial disease or ischemic heart disease. In addition, another strategy for combating disease processes, to target the transcriptional process, has been tested in a human trial. Transfection of cis-element double-stranded oligodeoxynucleotides is an especially powerful tool in a new class ofantigen strategies for gene therapy. Transfection of double-stranded oligodeoxynucleotides corresponding to the cis sequence will result in the attenuation of the authentic cis-trans interaction., leading to the removal of trans-factors from the endogenous cis-elements, with subsequent modulation of gene expression. Genetically modified vein grafts transfected with a decoy against E2F, an essential transcription factor in cell cycle progression,revealed apparent long-term potency in human patients. This review focuseson the future potential of gene therapy for the treatment of cardiovascular disease. (C) 2001 Elsevier Science Inc. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/12/20 alle ore 00:40:18